# A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

> **NCT03652077** · PHASE1 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 40 (actual)

## Conditions studied

- Cervical Cancer
- Gastric Cancer
- Stomach Cancer
- Gastroesophageal Junction Cancer
- Esophageal Cancer
- Hepatocellular Carcinoma
- Melanoma
- Uveal Melanoma
- Merkel Cell Carcinoma
- Mesothelioma
- MSI
- Non-small Cell Lung Cancer
- NSCLC
- Ovarian Cancer
- Squamous Cell Carcinoma of the Head and Neck
- Small Cell Lung Cancer
- Renal Cell Carcinoma
- RCC
- Triple-negative Breast Cancer
- Urothelial Carcinoma
- Mismatch Repair Deficiency

## Interventions

- **DRUG:** INCAGN02390

## Key facts

- **NCT ID:** NCT03652077
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-24
- **Primary completion:** 2021-08-18
- **Final completion:** 2021-08-18
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2021-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03652077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03652077, "A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT03652077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*